Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01759862 · ClinicalTrials.gov registry record · NA
Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01759862: Completed NA study, sponsored by Stanford University.
NCT01759862 is a NA study that has completed, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01759862, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate whether peri-transplant administration of a drug named aminophylline to children undergoing a kidney transplant from deceased donors improves early graft function and also projects on long term graft function.
Interventions
- DRUG Placebo
- DRUG Aminophylline
- OTHER Theophylline drug levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-11 |
| Est. Completion | 2017-07-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01759862
The ClinicalTrials.gov registry entry for NCT01759862 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01759862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01759862 about?
NCT01759862 is a clinical study titled "Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant". The aim of this study is to evaluate whether peri-transplant administration of a drug named aminophylline to children undergoing a kidney transplant from deceased donors improves early graft function and also projects on long term graft function.
What is the current status of trial NCT01759862?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2012-11. Estimated completion is 2017-07-25.
What interventions are being tested in trial NCT01759862?
The interventions under investigation include: Placebo (DRUG), Aminophylline (DRUG), Theophylline drug levels (OTHER).
Who is sponsoring clinical trial NCT01759862?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.